3rd Quarter - Report

VENN STRATEGIES for BIOMARIN PHARMACEUTICAL, INC.

Firm
Client
Income
$30,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Orphan drugs and rare diseases, matters related to drug reimbursement policy.

LobbyistCovered position, as disclosed
TIM CAREY —
AMY L REDL —
STEPHANIE SILVERMAN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Taxation/Internal Revenue Code TAX

Tax policy affecting bio-pharmaceutical companies.

LobbyistCovered position, as disclosed
TIM CAREY —
AMY L REDL —
STEPHANIE SILVERMAN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.